Loading…
← CockpitCompetitor Analysis › MYX.AX Mayne Pharma Group Ltd.Open in the cockpit ↗

Mayne Pharma Group Ltd.MYX.AXCompetitor analysis, valuation and peers

Australia · AUD·Health Care›Pharmaceuticals: Major
Momentum leader 99
Mkt cap
$333M
US dollars, full cap
Free float
86%
of shares outstanding
$/day
$2.25M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-19.8 pp
WACC 8.7%
Hurdle
+20 pp
Req g minus delivered
Next earnings
98 days
24 Feb 2027
Close · AUDA$6.06
1D+0.8%
1W+80.4%
1M+138.6%
3M+85.9%
6M+154.6%
YTD+94.9%
1Y+4.7%
ATR %5.2%
52w lowhigh0.2% off high

What Mayne Pharma does

Employees: 450

Mayne Pharma at a glance

Size Mayne Pharma (MYX.AX) is an Australia Health Care company (Pharmaceuticals: Major) with a market value of $333M, the 304th largest of 317 Australia companies the cockpit tracks. Shares closed at A$6.06 on 18 Nov 2026.

Performance Over six months the shares gained 154.6%, against -20.4% for the median peer and +1.2% for the Australia market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue fell 6.0% over the last twelve months (peer median +2.7%); the operating margin is -14.5% (peer median 3.0%).

Valuation It trades at 1.2× enterprise value to sales against a peer median of 2.8× (4th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +20 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 19.8 points below its cost of capital (8.7% WACC).

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

10020021 May 202621 Aug 202618 Nov 2026MYX.AX 259Peer median 79
Six months, rebased to 100: Mayne Pharma against the median of its 20 peers (local-currency closes).

Mayne Pharma financials

Reported figures in AUD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
RevenueA$384MA$384MA$408MA$388MA$184M
Revenue growth—-6%+5%+112%—
Gross profitA$190MA$192MA$186MA$159MA$26.8M
EBITDAA$8.14MA$29.8MA$45.6M-A$9.38M-A$121M
Net incomeA$24.5MA$24.5M-A$93.8M-A$174M-A$316M
Free cash flowA$12.7MA$12.7MA$9.83M-A$17.5M-A$51.5M
Capital expenditureA$3.32MA$3.32MA$27.8MA$20.9MA$220M
Total debtn/aA$43.2MA$41.3MA$38.8MA$47.5M

Quarterly statements and history in the cockpit →

Mayne Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%0%+50%+100%3015091875SOLARA1720002168600538005250AVIR368AINOINDSWFTLAB4886ALEMBICLTDMYX.AX6-month return →1-month return →
Up and to the right = strong over both horizons. Mayne Pharma is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×500×3015091875SOLARA1720INO600594INDSWFTLAB000790MYX.AXRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Mayne Pharma is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%301509SOLARA1720002168SECARE368A600594000790000153ALEMBICLTD3013314569MYX.AXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Mayne Pharma is the large dot.

Mayne Pharma competitors and peer comparison

How Mayne Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Mayne Pharma against its 20 peers (data as of 18 Nov 2026)
MeasureMYX.AXPeer medianRank in peer set
1-month return+138.6%-6.1%highest of 21
6-month return+154.6%-20.4%highest of 21
Distance from 52-week high-0.2%-35.7%highest of 21
Revenue growth (TTM)-6.0%+2.7%7th lowest of 20
Operating margin-14.5%3.0%6th lowest of 19
EV / Sales1.2×2.8×4th cheapest of 19
Growth the price implies (Req g, 7 yrs)19.0%8.6%4th most demanding of 13
Growth delivered (Del g)-0.9%+4.8%5th lowest of 13
Hurdle (Req g minus delivered)+19.9 pp+4.8 pp4th most demanding of 13
ROIC minus cost of capital-19.8 pp-7.0 pp4th lowest of 18
Net debt / EBITDA-4.8×-0.3×least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Mayne Pharma MYX.AXAustralia$333M+155%-6%-14%1.2×19.0%-0.9%
Kingchem (Liaoning) Life Science 301509.SZChina$333M-28%+3%6%1.4×9.2%+6.5%
BioDlink International 1875.HKHong Kong$334M-24%-51%-31%4.8×n/an/a
Solara Active Pharma Sciences SOLARA.NSIndia$334M+12%+27%8%2.4×38.3%-3.2%
Standard Chemical & Pharmaceutical 1720.TWTaiwan$329M-1%+5%22%1.8×-11.5%+10.3%
Chongqing Hifuture Information Technology 002168.SZChina$326M-27%+2%-6%7.4×14.3%-14.0%
Beihai Gofar Chuanshan Biological 600538.SSChina$326M-39%+10%-8%6.2×n/an/a
Foresee Pharmaceuticals 6576.TWOTaiwan$322M-12%+6%-104%21.4×n/an/a
Swedencare SECARE.STSweden$321M-24%+3%7%1.8×6.1%+62.1%
GC Corp. 005250.KSSouth Korea$321M-45%+2%3%1.1×n/an/a
Atea Pharmaceuticals AVIRUnited States$320M-5%n/an/an/an/an/a
Kitazato 368A.TJapan$317M+7%+9%52%3.1×-16.8%+5.4%
Inovio Pharmaceuticals INOUnited States$317M+37%+64%-25,954%921.6×n/an/a
Guizhou Yibai Pharmaceutical 600594.SSChina$351M-23%-26%-15%1.9×8.0%-11.3%
Ind-Swift Laboratories INDSWFTLAB.NSIndia$314M+150%+66%9%3.4×n/an/a
Chengdu Huasun Technology 000790.SZChina$312M-20%-36%-57%5.6×27.5%-6.4%
ASKA Pharmaceutical 4886.TJapan$354M-24%+11%n/an/an/an/a
Anhui Fengyuan Pharmaceutical 000153.SZChina$355M-17%-24%3%1.1×3.6%+3.1%
Alembic ALEMBICLTD.NSIndia$309M+25%-5%26%13.0×44.3%+26.7%
Enwei Pharmaceutical 301331.SZChina$308M-20%-7%5%2.1×14.0%+7.3%
KYORIN Pharmaceutical 4569.TJapan$360M-22%-6%2%0.5×6.7%+4.2%

Questions

Which companies are Mayne Pharma's closest peers?
The cockpit's peer set: Kingchem (Liaoning) Life Science (301509.SZ), BioDlink International (1875.HK), Solara Active Pharma Sciences (SOLARA.NS), Standard Chemical & Pharmaceutical (1720.TW), Chongqing Hifuture Information Technology (002168.SZ), Beihai Gofar Chuanshan Biological (600538.SS), Foresee Pharmaceuticals (6576.TWO), Swedencare (SECARE.ST).
Is Mayne Pharma expensive compared with its peers?
On ev / sales it trades at 1.2× against a peer median of 2.8×, 4th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +20 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Mayne Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned +154.6% against -20.4% for the median peer; over one year +4.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.